We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.95%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$39.9B
AUM Growth
+$891M
(+2.3%)
Cap. Flow
-$1.96B
Cap. Flow
% of AUM
-4.91%
Top 10 Holdings %
Top 10 Hldgs %
26.01%
Holding
846
New
122
Increased
198
Reduced
391
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$171M |
| 2 |
Sensata Technologies
ST
|
+$145M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$133M |
| 4 |
Amazon
AMZN
|
+$67.2M |
| 5 |
AbbVie
ABBV
|
+$65.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Otis Worldwide
OTIS
|
+$164M |
| 2 |
Ross Stores
ROST
|
+$110M |
| 3 |
Bank of America
BAC
|
+$94.4M |
| 4 |
Freeport-McMoran
FCX
|
+$92.4M |
| 5 |
Five Below
FIVE
|
+$89.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.1% |
| 2 | Healthcare | 19.47% |
| 3 | Consumer Discretionary | 12.58% |
| 4 | Financials | 11.29% |
| 5 | Communication Services | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Diodes
DIOD
$4.54B
| $37.6M | 0.09% |
666,014
+266,014
| +67% | +$13.5M |
|
227
Centene
CNC
$31.7B
| $37.4M | 0.09% |
641,812
-21,100
| -3% | -$1.31M |
|
228
Idexx Laboratories
IDXX
$46.5B
| $37.4M | 0.09% |
95,198
-3,100
| -3% | -$1.15M |
|
229
AstraZeneca
AZN
$250B
| $37M | 0.09% |
337,500
+250,000
| +286% | +$27.8M |
|
|
230
Ross Stores
ROST
$81.6B
| $37M | 0.09% |
396,020
-1,227,519
| -76% | -$110M |
|
231
Cabaletta Bio
CABA
$450M
| $36.9M | 0.09% |
3,404,760
-160,249
| -4% | -$1.84M |
|
232
BioMarin Pharmaceuticals
BMRN
$11.9B
| $36.8M | 0.09% |
484,000
-410,000
| -46% | -$41.5M |
|
233
HCA Healthcare
HCA
$88.5B
| $36.8M | 0.09% |
295,300
-9,500
| -3% | -$1.18M |
|
234
Morgan Stanley
MS
$336B
| $36.5M | 0.09% |
755,256
-43,400
| -5% | -$2.19M |
|
235
Rocket Companies
RKT
$37.4B
| $36M | 0.09% |
+1,807,276
| New | +$42.1M |
|
236
Sysco
SYY
$40.4B
| $35.4M | 0.09% |
568,624
+30,700
| +6% | +$1.79M |
|
237
Constellation Brands
STZ
$22.6B
| $35.3M | 0.09% |
186,067
-6,100
| -3% | -$1.11M |
|
238
Chipotle Mexican Grill
CMG
$42.7B
| $35M | 0.09% |
1,407,100
-55,000
| -4% | -$1.33M |
|
239
Agilent Technologies
A
$39.9B
| $35M | 0.09% |
346,506
-11,200
| -3% | -$1.08M |
|
|
STPK.U
240
DELISTED
Star Peak Energy Transition Corp. Units, each consisting of one share of Class A common stock, and o
STPK.U
| $34.9M | 0.09% |
+3,400,000
| New | +$34.4M |
|
|
BNY
241
Bank of New York Mellon
BNY
$108B
| $34.8M | 0.09% |
1,013,650
-59,900
| -6% | -$2.18M |
|
242
Teleflex
TFX
$6.15B
| $34.8M | 0.09% |
102,121
-36,700
| -26% | -$13.6M |
|
243
Carrier Global
CARR
$52.7B
| $34.7M | 0.09% |
1,134,772
-2,999,510
| -73% | -$84.9M |
|
244
Natera
NTRA
$38B
| $34.3M | 0.09% |
475,000
+100,000
| +27% | +$5.69M |
|
245
Saic
SAIC
$5.25B
| $34.2M | 0.09% |
435,988
-480,600
| -52% | -$37.9M |
|
246
Flowserve
FLS
$10B
| $33.9M | 0.08% |
1,241,255
+65,674
| +6% | +$1.91M |
|
247
WEC Energy
WEC
$35.2B
| $33.8M | 0.08% |
+348,515
| New | +$32.5M |
|
248
Verisk Analytics
VRSK
$24.7B
| $33.7M | 0.08% |
181,800
-5,400
| -3% | -$989K |
|
249
Annexon
ANNX
$918M
| $33.5M | 0.08% |
+1,109,830
| New | +$26M |
|
250
Monster Beverage
MNST
$92.1B
| $33.5M | 0.08% |
834,522
-26,800
| -3% | -$1.06M |
|
Similar funds
Adage Capital Partners's Q3 2020 Portfolio in Review
As of Q3 2020, Adage Capital Partners held 846 positions worth $39.9B, up 2.3% from $39.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Adage Capital Partners withdrew a net $1.96B in Q3 2020, closing 98 positions and reducing 391 holdings. Its most notable exit was Pfizer, an estimated $60.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $134M.
- Adage Capital Partners's largest Q3 2020 buy was Bristol-Myers Squibb: 2,215,804 shares worth $134M.
- Adage Capital Partners added most to Johnson & Johnson in Q3 2020, an estimated $171M increase.
- Adage Capital Partners's biggest Q3 2020 reduction was Otis Worldwide, cutting an estimated $164M.
- Adage Capital Partners fully exited Pfizer in Q3 2020, selling an estimated $60.9M.
- Adage Capital Partners's ten largest holdings make up 26% of its $39.9B portfolio in Q3 2020.
- Adage Capital Partners opened 122 new positions and closed 98 in Q3 2020.
- Adage Capital Partners's portfolio value rose 2.3% quarter-over-quarter to $39.9B.
Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.